MetaCap

ANI Pharmaceuticals (ANIP) vs Precigen (PGEN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Precigen (PGEN) has outperformed ANI Pharmaceuticals (ANIP) over the past year, gaining 8.5% versus a loss of 14.0%. Over five years, ANIP leads with a +68.1% price change compared with +9.1% for PGEN. ANI Pharmaceuticals is the larger company by market cap ($1.56 billion vs $1.51 billion), about 1.0 times the size, while Precigen is growing revenue faster (+146.7% vs +43.8%).

On valuation, ANI Pharmaceuticals trades at a lower trailing P/E (13.9x vs 38.3x for Precigen). ANI Pharmaceuticals converts more of its revenue into profit, with a net margin of 8.9% versus -2588.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANIP-14.01%PGEN+8.51%
+128%+50%-27%
Nov 21, 20251 yearNov 20, 2026
ANIP+57.44%PGEN+11.97%
+138%+23%-92%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANIP versus PGEN key metrics
MetricANIPPGEN
Share price$68.55$4.21
Market cap$1.56B$1.51B
1-day change-0.84%+1.20%
YTD return-13.16%+0.72%
1-year return-14.01%+8.51%
5-year return+68.14%+9.07%
P/E ratio (TTM)13.9038.27
Forward P/E6.72—
EPS (TTM)$4.93$0.11
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$883.37M$9.68M
Revenue growth (YoY)+43.78%+146.73%
Net income (latest FY)$78.34M$-250.64M
Gross margin61.36%—
Operating margin12.58%-1141.13%
Net margin8.87%-2588.21%
52-week high$87.76$8.98
52-week low$67.14$3.04
Distance from 52-week high-21.89%-53.12%
Analyst consensusbuybuy
Avg. price target upside+50.81%+224.70%
Average volume420.66K5.68M
Shares outstanding22.72M358.55M
Employees970160
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PGEN has outperformed ANIP by 22.5 percentage points over the past year.
  • Precigen trades at a higher earnings multiple (38.3x vs 13.9x trailing P/E).
  • ANI Pharmaceuticals is more profitable, keeping 8.9 cents of every revenue dollar as net income versus -2588.2 cents for Precigen.
  • Precigen grew revenue faster in its latest fiscal year (+146.73% vs +43.78%).

About ANI Pharmaceuticals

ANIP stock →

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.

Health Care · Biotechnology: Pharmaceutical Preparations · 970 employees

About Precigen

PGEN stock →

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 160 employees

ANIP vs PGEN FAQ

Which is bigger, ANI Pharmaceuticals or Precigen?

ANI Pharmaceuticals (ANIP) is larger, with a market capitalization of $1.56B compared with $1.51B for Precigen (PGEN).

Which stock has performed better over the past year, ANIP or PGEN?

PGEN returned +8.51% over the past 12 months, compared with -14.01% for ANIP (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, ANIP or PGEN?

ANIP has the lower trailing P/E at 13.9, versus 38.3 for PGEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are ANI Pharmaceuticals and Precigen in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons